B
Biomea Fusion, Inc. (BMEA)
NMS – Real vaqt narxi. Valyuta: USD
1.58
+0.01 (0.64%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
1.58
+0.01 (0.64%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Biomea Fusion, Inc., klinik bosqichdagi diabet va semirish dorilari kompaniyasi, diabet va semirish bilan kasallangan bemorlarni davolash uchun og'iz orqali yuboriladigan dorilarni kashf qilish va ishlab chiqishga qaratilgan. Kompaniyaning yetakchi klinik dasturining dori nomzodlari quyidagilardir: COVALENT-111 va COVALENT-112, ular 1-va 2-tip diabetni davolash uchun ikovamenibni II bosqich klinik sinovlaridan o'tkazgan; COVALENT-211, insulin yetishmovchiligi bo'lgan 2-tip diabetni davolash uchun ikovamenibni II bosqich klinik sinovidan o'tayotgan; va COVALENT-212, 2-tip diabetni davolash uchun ikovamenibni II bosqich klinik sinovidan o'tayotgan. Kompaniya, shuningdek, semirishni davolash uchun I bosqichli glyukagon-o'xshash peptid-131 klinik sinovidan o'tayotgan BMF-650ni ishlab chiqmoqda. Kompaniya 2017-yilda ro'yxatga olingan va shtab-kvartirasi Kaliforniyaning San-Karlos shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts |
| Dr. Michael J. M. Hitchcock Ph.D. | Interim CEO & Director |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Research |
| Mr. Heow Tan | Chief Technology & Quality Officer |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | 8-K | d142809d8k.htm |
| 2026-04-27 | DEF 14A | bmea-20260427.htm |
| 2026-04-27 | ARS | ars_2025.pdf |
| 2026-03-24 | 10-K | bmea-20251231.htm |
| 2026-02-25 | 8-K | d95198d8k.htm |
| 2026-01-14 | 8-K | d747443d8k.htm |
| 2026-01-06 | S-8 | d10984ds8.htm |
| 2025-11-04 | 10-Q | bmea-20250930.htm |
| 2025-10-07 | 8-K | d237219d8k.htm |
| 2025-10-06 | 8-K | d79150d8k.htm |
| Mr. Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property |